These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 26785433)
1. Malignant Hyperthermia, Exertional Heat Illness, and RYR1 Variants: The Muscle May Not Be the Brain. Sagui E Anesthesiology; 2016 Feb; 124(2):510. PubMed ID: 26785433 [No Abstract] [Full Text] [Related]
2. In Reply. Hopkins PM; Fiszer D; Shaw MA; Roiz de Sa D Anesthesiology; 2016 Feb; 124(2):511. PubMed ID: 26785434 [No Abstract] [Full Text] [Related]
3. Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness. Fiszer D; Shaw MA; Fisher NA; Carr IM; Gupta PK; Watkins EJ; Roiz de Sa D; Kim JH; Hopkins PM Anesthesiology; 2015 May; 122(5):1033-46. PubMed ID: 25658027 [TBL] [Abstract][Full Text] [Related]
4. Is there a link between malignant hyperthermia and exertional heat illness? Muldoon S; Deuster P; Brandom B; Bunger R Exerc Sport Sci Rev; 2004 Oct; 32(4):174-9. PubMed ID: 15604937 [TBL] [Abstract][Full Text] [Related]
5. Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia. Schiemann AH; Stowell KM Br J Anaesth; 2016 Jul; 117(1):124-8. PubMed ID: 27147545 [TBL] [Abstract][Full Text] [Related]
6. Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference. Riazi S; Kraeva N; Muldoon SM; Dowling J; Ho C; Petre MA; Parness J; Dirksen RT; Rosenberg H Can J Anaesth; 2014 Nov; 61(11):1040-9. PubMed ID: 25189431 [TBL] [Abstract][Full Text] [Related]
7. Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and calsequestrin-1 gene polymorphisms. Capacchione JF; Sambuughin N; Bina S; Mulligan LP; Lawson TD; Muldoon SM Anesthesiology; 2010 Jan; 112(1):239-44. PubMed ID: 20010423 [No Abstract] [Full Text] [Related]
8. No C1840 to T mutation in RYR1 in malignant hyperthermia. Hall-Curran JL; Stewart AD; Ball SP; Halsall JP; Hopkins PM; Ellis FR Hum Mutat; 1993; 2(4):330. PubMed ID: 8401544 [No Abstract] [Full Text] [Related]
9. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review. Kraeva N; Sapa A; Dowling JJ; Riazi S Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467 [TBL] [Abstract][Full Text] [Related]
11. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link? Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia. Beam TA; Loudermilk EF; Kisor DF Physiol Genomics; 2017 Feb; 49(2):81-87. PubMed ID: 28011884 [TBL] [Abstract][Full Text] [Related]
13. Investigating the genetic susceptibility to exertional heat illness. Gardner L; Miller DM; Daly C; Gupta PK; House C; Roiz de Sa D; Shaw MA; Hopkins PM J Med Genet; 2020 Aug; 57(8):531-541. PubMed ID: 32054689 [TBL] [Abstract][Full Text] [Related]
14. RYR1 variant c.38T>G, p.Leu13Arg causes hypersensitivity of the ryanodine receptor-1 and is pathogenic for malignant hyperthermia. van den Bersselaar LR; Greven T; Bulger T; Voermans NC; van Petegem F; Schiemann AH; Parker R; Burling SM; Jungbluth H; Stowell KM; Kamsteeg EJ; Snoeck MMJ Br J Anaesth; 2021 Aug; 127(2):e63-e65. PubMed ID: 34127251 [No Abstract] [Full Text] [Related]
15. Comparison of the segregation of the RYR1 C184OT mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. Hogan K Anesthesiology; 1996 Feb; 84(2):29A-30A. PubMed ID: 8602659 [No Abstract] [Full Text] [Related]
16. RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction. Kruijt N; den Bersselaar LV; Snoeck M; Kramers K; Riazi S; Bongers C; Treves S; Jungbluth H; Voermans N Curr Pharm Des; 2022; 28(1):2-14. PubMed ID: 34348614 [TBL] [Abstract][Full Text] [Related]
19. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. Riazi S; Kraeva N; Hopkins PM Anesthesiology; 2018 Jan; 128(1):168-180. PubMed ID: 28902675 [TBL] [Abstract][Full Text] [Related]
20. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in patients with malignant hyperthermia. Rueffert H; Kraus H; Olthoff D; Deutrich C; Froster UG Hum Mutat; 2001 Mar; 17(3):238. PubMed ID: 11241852 [No Abstract] [Full Text] [Related] [Next] [New Search]